TC Biopharm (NASDAQ:TCBPW) Shares Down 9.8%
TC Biopharm (NASDAQ:TCBPW) Shares Down 9.8%
TC Biopharm (Holdings) Plc (NASDAQ:TCBPW – Get Rating) shares were down 9.8% during mid-day trading on Friday . The stock traded as low as $0.11 and last traded at $0.11. Approximately 1,500 shares traded hands during mid-day trading, a decline of 97% from the average daily volume of 58,702 shares. The stock had previously closed at $0.13.
TC Biopharm（Holdings）Plc（纳斯达克股票代码：TCBPW — 获取评级）股价在周五午盘交易中下跌9.8％。该股的交易价格低至0.11美元，最后一次交易价格为0.11美元。午盘交易中约有1,500股交易，较平均每日交易量58,702股下降了97％。该股此前收于0.13美元。
TC Biopharm Stock Down 9.8 %
TC Biopharm股价下跌9.8％
The firm's fifty day moving average is $0.14 and its 200-day moving average is $0.15.
该公司的五十天移动平均线为0.14美元，其200天移动平均线为0.15美元。
Institutional Trading of TC Biopharm
TC Biopharm 的机构交易
An institutional investor recently bought a new position in TC Biopharm stock. Nantahala Capital Management LLC bought a new position in shares of TC Biopharm (Holdings) Plc (NASDAQ:TCBPW – Get Rating) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 235,294 shares of the company's stock, valued at approximately $117,000.
一位机构投资者最近购买了TC Biopharm股票的新头寸。根据最近向美国证券交易委员会（SEC）提交的13F表格，Nantahala Capital Management LLC在第一季度购买了TC Biopharm（Holdings）（纳斯达克股票代码：TCBPW — Get Ratinge）股票的新头寸。该机构投资者购买了该公司235,294股股票，价值约11.7万美元。
TC Biopharm Company Profile
TC Biopharm 公司简介
(Get Rating)
（获取评分）
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its products pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; ImmuniStim, an unmodified cell therapy to treat COVID-19; TCB009 for the GI-tract cancer treatment; and TCB005/TCB006 that are allogeneic co-stimulatory GD-T CAR pre-clinical drug candidates would target antigens expressed on various solid tumor types.
TC Biopharm（Holdings）Plc是一家临床阶段的生物制药公司，专注于开发基于其异体伽玛ΔT细胞平台的免疫疗法产品。其产品线包括OmnImmune，一种用于治疗急性髓系白血病的未改性细胞疗法；Immunistim，一种用于治疗 COVID-19 的未改性细胞疗法；用于治疗胃肠道癌的 TCB009；以及同种异体共刺激 GD-T CAR 临床前候选药物将靶向在各种实体瘤类型上表达的抗原 TCB005/TCB006。
See Also
另见
- Get a free copy of the StockNews.com research report on TC Biopharm (TCBPW)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don't Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
- 免费获取 StockNews.com 关于 TC Biopharm (TCBPW) 的研究报告
- 这家具有巨大增长前景的小型科技公司已接近买入点
- 不要追高联邦快递，等着回调
- 防御性科技投资组合的3只股票
- 在这 3 头摇钱树身上挤出股息
- 欧洲提高利率，美联储应该效仿吗？
Receive News & Ratings for TC Biopharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TC Biopharm and related companies with MarketBeat.com's FREE daily email newsletter.
接收 TC Biopharm 每日的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收TC Biopharm及相关公司的最新新闻和分析师评级的简明每日摘要。